Aptevo Therapeutics Inc
$ 5.28
-5.88%
17 Apr - close price
- Market Cap 6,629,500 USD
- Current Price $ 5.28
- High / Low $ 5.69 / 5.26
- Stock P/E N/A
- Book Value 17.42
- EPS -87.27
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.77 %
- ROE -2.35 %
- 52 Week High 486.00
- 52 Week Low 3.80
About
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.
Analyst Target Price
$21.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-01 | 2025-12-31 | 2025-11-06 | 2025-08-11 | 2025-05-15 | 2025-02-14 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-05 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -5.9108 | None | -2.23 | -8.4 | -87.8 | -178.8 | -355.2 | -1.67 | -9.95 | -6.16 | -0.5 | -1.23 |
| Estimated EPS | None | -8.09 | -3.78 | -83.2 | -84.2 | -155 | -421.8 | -6.55 | -12.84 | -18.04 | -0.75 | -1.12 |
| Surprise | 0 | 0 | 1.55 | 74.8 | -3.6 | -23.8 | 66.6 | 4.88 | 2.89 | 11.88 | 0.25 | -0.11 |
| Surprise Percentage | None% | None% | 41.0053% | 89.9038% | -4.2755% | -15.3548% | 15.7895% | 74.5038% | 22.5078% | 65.8537% | 33.3333% | -9.8214% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -5.6 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APVO
2026-04-12 18:09:17
This article announces that Aptevo Therapeutics (APVO) has received an analyst upgrade to a "buy" rating. It suggests that this upgrade is based on reasons that will appeal to investors. The article implies further details regarding the rationale for the upgrade will follow.
2026-04-11 01:39:21
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy) due to positive shifts in its earnings outlook, which are a key indicator for stock performance. This upgrade reflects more optimistic earnings forecasts, suggesting the company's core business is strengthening. The Zacks system, unlike Wall Street analysts, provides an objective assessment based on earnings estimate revisions, which have historically preceded stock price movements.
2026-04-10 23:39:04
Aptevo Therapeutics Inc. (APVO) has received a Zacks Rank #2 (Buy) rating due to improved earnings forecasts, indicating a positive shift in its financial outlook. The Zacks rating system, which is based on changes in consensus earnings per share estimates, suggests that the company's core business is strengthening. This upgrade places Aptevo Therapeutics among the top 20% of stocks covered by Zacks, implying potential for future stock price gains.
2026-04-07 10:39:21
This analysis of Aptevo Therapeutics Inc. (APVO) advises against buying the stock for beginner, long-term investors due to poor financial performance, lack of positive catalysts, and a mixed to bearish technical outlook. The company reported zero revenue growth and a significant net income drop in Q4 2025, with no analyst ratings available. Technical indicators show a slight bullish momentum from MACD but bearish moving averages and a neutral RSI, predicting potential negative returns in the short to medium term.
2026-04-02 08:09:44
This article provides a technical analysis and stock price forecast for Aptevo Therapeutics Inc (APVO), with data as of April 2, 2026. It indicates a "Strong Sell" consensus based on various technical indicators, including moving averages and oscillators. The report highlights key support and resistance levels, RSI, and MACD signals, noting that APVO is trading below its 200-day moving average.
2026-03-27 18:09:41
Aptevo Therapeutics' investigational drug, mipletamig, has shown promising interim results in its RAINIER clinical trial for frontline Acute Myeloid Leukemia (AML) patients. When used in combination with standard-of-care treatments, mipletamig achieved an 86% clinical benefit rate and a 79% remission rate, with 55% of remitted patients reaching MRD-negative status. The therapy also demonstrated a favorable safety profile, notably without inducing cytokine release syndrome, making it a potential advancement for older or medically unfit AML patients.
